Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07030127 | A Study of LY3985863 in Healthy Participants | PHASE1 | COMPLETED | 24 | — | — | Aug 11, 2025 | Feb 24, 2026 | Mar 11, 2026 | 1 | China |
A summary of TEAEs and SAEs regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3985863 | EXPERIMENTAL | Administered subcutaneously (SC) |
| Placebo | PLACEBO_COMPARATOR | Administered SC |
| Name | Type | Description |
|---|---|---|
| LY3985863 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Are native Chinese participants * Are overtly healthy * Have body weight of at least 50.0 kilogram (kg) for male or 45.0 kg for female and a body mass index of 20.0 to 30.0 kilogram per square meter (kg/m²), inclusive * Have a stable body weight within 3 months Exclusion Crit...